NCT02742051View on ClinicalTrials.gov

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 14, 2020

Study Completion Date

March 14, 2020

Conditions
Breast Cancer
Interventions
DRUG

Everolimus

Neoadjuvant endocrine therapy

DRUG

Letrozole

Neoadjuvant endocrine therapy

DRUG

Fluorouracil

Neoadjuvant chemotherapy

DRUG

Epirubicin

Neoadjuvant chemotherapy

DRUG

Cyclophosphamide

Neoadjuvant chemotherapy

Trial Locations (1)

510120

Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT02742051 - A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | Biotech Hunter | Biotech Hunter